ライフサイエンスコーパス: AHI

1 AHI also positively correlated with beta power in the OS

2 AHI incidence increased in both HIV-infected and HIV-neg

3 AHI incidence rose from 1.1/100 person-years (95 confide

4 AHI incidence was determined in HIV-infected and in pree

5 AHI was not associated with cancer incidence in the adju

6 14.9, and > or =15, respectively (P=0.0049, AHI > or =15 versus <1).

7 From 2014 to 2017, 108 AHIs (80 first infections, 28 reinfections) were reporte

8 I, 55 +/- 6/h) and control subjects (n = 14; AHI, 4 +/- 1/h) were extracted from the genioglossus mus

9 1,655 MUPTs from patients with OSA (n = 17; AHI, 55 +/- 6/h) and control subjects (n = 14; AHI, 4 +/

10 ction (AHI) detection was evaluated using 21 AHI specimens (range, 1,520 to 500,000 copies/ml) previo

11 I 15 to 29.9, OR=2.38 [95% CI 1.30 to 4.38]; AHI > or =30, OR=2.24 [95% CI 1.10 to 4.54]).

12 There were 19 (42%) AHI participants who referred a single partner that retu

13 Among 45 AHI participants with HIV-1 sequences, none was phylogen

14 positive, negative) were: AHI>=5=0.99, 0.78; AHI>=10=0.96, 0.89; and AHI>=15=0.96, 0.89.

15 edominant obstructive apneas (OA) was 12.8% (AHI >/=5 events/h with OAs >50%; nighttime: 14.7%; dayti

16 small, with only 14% of the records having a AHI-ODI difference exceeding >5/hr, and 6% exceeding >10

17 requires symptoms in addition to an abnormal AHI (>/=5/h with symptoms, prevalence 2%-4%).

18 f this study were to determine how OA alters AHI and four phenotypic traits (upper-airway anatomy/col

19 1 event/h, and severe OSAS was defined by an AHI greater than or equal to 5 events/h.

20 Sleep-disordered breathing was defined by an AHI of at least 10 (mild to moderate) or of at least 15

21 In adolescents free of known CVD, an AHI > or =5 is associated with increasing levels of CRP,

22 the treatment group (35 [51%] of 68) had an AHI reduction from baseline of 50% or greater at 6 month

23 litus with an AHI of 15 or greater versus an AHI of less than 5 was 2.30 (95% confidence interval, 1.

24 mprised the control group, and those with an AHI greater than or equal to 10 were diagnosed with OSA

25 Fifteen patients (10 men) with an AHI greater than or equal to 20 (10 OSA; 5 CSA) particip

26 ician diagnoses of diabetes mellitus with an AHI of 15 or greater versus an AHI of less than 5 was 2.

27 loping diabetes mellitus within 4 yr with an AHI of 15 or more compared with an AHI of less than 5 wa

28 r with an AHI of 15 or more compared with an AHI of less than 5 was 1.62 (95% confidence interval, 0.

29 betes compared with 2.8% of subjects with an AHI of less than 5.

30 OSA was determined using 132 records with an AHI>=5 and at least 20 mins of recording time in both su

31 By ordinal logistic regression analysis, AHI was significantly associated with age (odds ratio [O

32 : AHI>=5=0.99, 0.78; AHI>=10=0.96, 0.89; and AHI>=15=0.96, 0.89.

33 ter adjusting for percent body fat, BMI, and AHI.

34 Using AASM 2012 diagnostic criteria and AHI threshold values of five or more events per h and 15

35 an snoring sound intensity (301-850 Hz), and AHI could significantly predict the surgical response.

36 of the relationship between weight loss and AHI improvement.Conclusions: Weight loss reduced volumes

37 In severe OSA subjects (n = 22), NFI and AHI had a Spearman correlation coefficient of 0.44 (p =

38 In the total sample, NFI and AHI were moderately correlated (r = 0.358; p = 0.001).

39 it by 3.9 +/- 2.4 cmH(2) O (mean +/- SD) and AHI by 69 +/- 19%.

40 one was phylogenetically-linked with another AHI index.

41 ty, specificity, area under the curve (AUC), AHI, Epworth Sleepiness Scale (ESS) scores, blood pressu

42 ex with men (MSM) undergoing community-based AHI screening in San Diego, California.

43 man correlation coefficient of 0.246 between AHI severity and periodontal disease severity categories

44 , there was a consistent association between AHI and all-cause mortality.

45 r =60 years, no adjusted association between AHI and systolic/diastolic hypertension was found.

46 indicated a significant association between AHI severity categories and percentage of sites with pla

47 We also analysed partial correlation between AHI and the absolute values of the EEG frequency bands.

48 rity of SDB (P value for interaction between AHI and FEV1, 0.004).

49 The relationship between AHI and RNFL parameters was also evaluated.

50 index was significantly associated with both AHI and hypoxemia index after adjustment for age, sex, e

51 s at 18q21 suggestively associated with both AHI and percentage time SaO2 < 90% (P < 10-3).

52 1-4.6) when the diagnosis was established by AHI >/=10/h).

53 ABA levels, but not Glx, and SDB severity by AHI (r = -0.68, P < 0.0001), and a positive correlation

54 This study is the first to characterize AHI among Nigerians identified as HIV infected before se

55 Under each condition, AHI and the phenotypic traits were assessed.

56 e efficacious than MAD in reducing AHI (CPAP AHI, 4.5 +/- 6.6/h; MAD AHI, 11.1 +/- 12.1/h; P < 0.01)

57 orrelation was found between the PSG-derived AHI and the WP- derived AHI (r=0.80, p<0.0001).

58 ere was a good agreement between PSG-derived AHI and WP-derived AHI (mean difference of AHI: -0.02+/-

59 ween the PSG-derived AHI and the WP- derived AHI (r=0.80, p<0.0001).

60 ement between PSG-derived AHI and WP-derived AHI (mean difference of AHI: -0.02+/-13.2).

61 ted annual costs of 3 algorithms that detect AHI based on HIV nucleic acid amplification testing (Ear

62 During AHI, a viral latent pool reservoir develops, the immune

63 nst heterologous T/F viruses appeared during AHI at the first time point sampled in each of the 5 don

64 Virologic suppression of HIV-1 by ART during AHI impedes seroconversion to biomarkers of infection, l

65 ecificity of antiviral CD8(+) T cells during AHI.

66 mpen leukocyte extravasation into CNS during AHI.

67 assays, and a model of viral dynamics during AHI.

68 that were shown to drive HIV-1 escape during AHI.

69 ART initiation during AHI differentially impacts the brain compartment, with m

70 unctions were assessed longitudinally during AHI in five donors from the CHAVI 001 cohort using a CD8

71 he faster and stronger cytokine storm during AHI could promote disease progression.

72 rtant differences are 15 events per hour for AHI and 2 units for ESS.

73 ients younger than 65 years (adjusted HR for AHI >43 vs. <18.7, 1.66; 95% CI, 1.04-2.64).

74 demonstrated improved efficiency and PPV for AHI case detection compared to individual NAAT.

75 ficiency and test performance of testing for AHI, but optimizing the pooling algorithm can be difficu

76 termined the ability of circulating IgG from AHI to bind infectious versus noninfectious virions.

77 us control groups achieving a 50% or greater AHI reduction from baseline to 6 months, measured by a f

78 retic peptide level, renal dysfunction, 24-h AHI, CAI, and time with oxygen saturation of <90% were i

79 A higher AHI and higher hypoxemia index were also associated with

80 Additionally, higher AHI results were associated with thinner RNFL superotemp

81 Children with higher AHI (>5 per hour of total sleep time) were significantly

82 oss the groups, with individuals with higher AHI showing worse performance.

83 ts with OSA on placebo (AHI > 10 events/hr), AHI was lowered by 74% (62-88%) (P < 0.001) and all 15 p

84 alternative to an auto-scored Level III HSAT AHI in the characterization of POSA based on a 3% desatu

85 her odds of systolic/diastolic hypertension (AHI 15 to 29.9, OR=2.38 [95% CI 1.30 to 4.38]; AHI > or

86 data derived from Advanced Himawari Imager (AHI), one of new-generation geostationary satellite sens

87 Improved AHI with weight loss was mediated by reductions in tongu

88 ignificant difference, oxygen versus air, in AHI, subjective sleepiness, or objective sleepiness.

89 ary outcome was baseline to 2-year change in AHI on diagnostic polysomnography scored by staff blinde

90 terval 1.02 to 1.26] per 10-unit increase in AHI).

91 uction in LG and the percentage reduction in AHI (r =0.660, P =0.05).

92 e independent predictors of the reduction in AHI (r(2) = 0.70; P = 0.001).

93 The reduction in AHI correlated with the reduction in total body ECFV (r

94 sult in a statistically greater reduction in AHI despite major differences in weight loss.

95 e independent predictors of the reduction in AHI.

96 were strongly correlated with reductions in AHI (Pearson's rho = 0.62, P < 0.0001); results remained

97 tions aimed at controlling cytokine storm in AHI may be beneficial to slow eventual disease progressi

98 Apnoea/hypopnoea incidence (AHI), breathing variability, respiratory-cardiovascular

99 imal effect on markers of arousal (including AHI), subjective sleepiness, or objective sleepiness.

100 , 0.3-0.6 SDs), all favoring CPAP, including AHI (15 +/- 16 and 8 +/- 6/hour, respectively), effectiv

101 eased chemoreflex sensitivity, and increased AHI (6 +/- 2/h vs. 14 +/- 3/h), RRVI (5 +/- 3/h vs. 20 +

102 The OR for increased AHI per 1-unit increase in BMI decreased from 1.21 (95%

103 The OR for increased AHI per 10-year age increase was 2.41 in women (95% CI,

104 Increasing AHI was significantly associated with decreasing AVR (P

105 tionship was demonstrated between increasing AHI and attenuated retinal vascular pulsation amplitude

106 uantitative phenotypes apnea-hypopnea index (AHI) and body mass index (BMI).

107 or association between apnea-hypopnea index (AHI) and health outcomes among community-based participa

108 mnographically derived apnea-hypopnea index (AHI) and hypoxemia index (percent of sleep time with oxy

109 as quantified with the apnea hypopnea index (AHI) and oxygen desaturation measures.

110 Apnea-hypopnea index (AHI) and percent nighttime with oxygen saturation less t

111 ationships between REM apnea-hypopnea index (AHI) and prevalent hypertension.

112 categorized using the apnea-hypopnea index (AHI) and the hypoxemia index (percent sleep time below 9

113 rtality, with FEV1 and apnea-hypopnea index (AHI) as the primary exposure indicators along with sever

114 , defined as having an Apnea-Hypopnea Index (AHI) greater than 15 as assessed by polysomnography, and

115 models, patients with apnea-hypopnea index (AHI) greater than 30 had a 30% higher hazard of developi

116 OSAS was defined by an apnea/hypopnea index (AHI) greater than or equal to 1 event/h, and severe OSAS

117 day, subjects with an apnea-hypopnea index (AHI) greater than or equal to 20 had fluid removed by UF

118 al disease between the apnea-hypopnea index (AHI) groups, with a negligible Spearman correlation coef

119 Women with an apnea-hypopnea index (AHI) less than 10 comprised the control group, and those

120 Women with an apnea-hypopnea index (AHI) less than 10 were the control group.

121 Patients with an apnea-hypopnea index (AHI) less than 15 were the control group.

122 orrelation between the apnea hypopnea index (AHI) measured by polysomnography and respiratory events

123 nt hypertension and an apnea-hypopnea index (AHI) of 15 or higher.

124 ion of 45% or less, an apnea-hypopnea index (AHI) of 15 or more events (occurrences of apnea or hypop

125 7% of subjects with an apnea-hypopnea index (AHI) of 15 or more had a diagnosis of diabetes compared

126 (<6 months) OSA and an apnea-hypopnea index (AHI) of 20 events/hour or more.

127 ce varies based on the apnea-hypopnea index (AHI) threshold used for the evaluation (>/=5 events/h, p

128 The apnea-hypopnea index (AHI) was derived from standardized sleep tests; diabetes

129 cal data including the apnea-hypopnea index (AHI), and nocturnal oxygen saturation (O2sat) parameters

130 uccess at reducing the apnea-hypopnea index (AHI), and predicting responders is challenging.

131 P 8/14 levels and with apnea-hypopnea index (AHI), BMI z score, and apolipoprotein B levels.

132 s were the obstructive apnea-hypopnea index (AHI), central apnea index (CAI >/= 5), and Cheyne-Stokes

133 groups on the basis of apnea-hypopnea index (AHI), followed by comparisons of cognitive function, wit

134 rimary OSA traits [the apnea hypopnea index (AHI), overnight average oxyhemoglobin saturation (SaO2)

135 tained measurements of apnea-hypopnea index (AHI), peripheral oxygen saturation level, and number of

136 aturation index (ODI), apnea-hypopnea index (AHI), subjective sleepiness (Epworth Sleepiness Scale sc

137 SAS and calculation of Apnea-Hypopnea Index (AHI).

138 ask leak, and residual apnea-hypopnea index (AHI).

139 ve been defined by the apnea-hypopnea index (AHI).

140 ate with reductions in apnea-hypopnea index (AHI).Methods: A total of 67 individuals with obesity and

141 ub-groups based on the apnea/hypopnea index (AHI): mild, moderate, or severe OSA.

142 ity was defined by the apnea-hypopnea index (AHI): severe >30, moderate >15-30, mild 5-15, and contro

143 come measures included apnea-hypopnea index (AHI; average number of apneas plus hypopneas per hour of

144 come measures were the apnea-hypopnea index (AHI; ie, the number of apnea and hypopnea events/h; 15-3

145 come measures were the apnea-hypopnea index (AHI; the number of apnea or hypopnea events per hour, wi

146 OSA (mean +/-s.e.m., apnoea-hypopnoea index (AHI) 48.9 +/- 5.9 events h(-1)) during non-rapid eye mov

147 as quantified as the apnoea-hypopnoea index (AHI) and respiratory rate variability index (RRVI).

148 ion of an equivalent apnoea-hypopnoea index (AHI) for publications that used different criteria.

149 ble patients with an apnoea-hypopnoea index (AHI) of at least 20 events per h, tested by a polysomnog

150 ity despite a normal apnoea-hypopnoea index (AHI).

151 The apnoea-hypopnoea index (AHI)was assessed on separate nights using standard polys

152 ce of predominant CAs (apnea/hypopnea index [AHI] >/=5 events/h, with CA of >50%) was 64.8% (nighttim

153 s diagnosed with SAHS (apnea/hypopnea index [AHI] >or= 5/hour, and >or= 2 symptoms including sleepine

154 o have normal results (apnea hypopnea index [AHI] <5).

155 /=50% reduction in the apnea-hypopnea index [AHI] and <10 events/hour) in patients with OSAHS.

156 tified as free of OSA (apnea-hypopnea index [AHI] of <5 events/h and not treated) by 2 baseline polys

157 er 10-unit increase in apnea-hypopnea index [AHI]) but not in older men or in women of any age.

158 h moderate-severe OSA (apnea hypopnea index [AHI], 25.6 [SD 12.3]) were randomly assigned to a treatm

159 sleep apnea probands (apnea-hypopnea index [AHI]: 43.2 +/- 26.3 events/h), 55 proband siblings (AHI:

160 ynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and genioglossus responsiveness (

161 with positional OSAS (apnea-hypopnea index [AHI]supine:AHInon-supine >/= 2) were prospectively enrol

162 uctive sleep apnoea (apnoea-hypopnoea index [AHI] >=5 to <=15 events per h using either AASM 2007 or

163 cacious (reduction in apnoea-hypopnea index; AHI) in patients with a posteriorly-located tongue and l

164 on indices (ODI) and apnea-hypopnea indices (AHI) according to two different definitions for position

165 CD8(+) T cells during acute HIV-1 infection (AHI) can elucidate the nature of the CD8(+) responses th

166 (Ab) produced during acute HIV-1 infection (AHI) is critical for defining antibody antiviral capabil

167 lly understood during acute HIV-1 infection (AHI).

168 imen pooling scheme for acute HIV infection (AHI) detection was evaluated using 21 AHI specimens (ran

169 ted during acute seronegative HIV infection (AHI) in whom RCI has been stringently quantified, we fou

170 al therapy (ART) during acute HIV infection (AHI) interrupts viral dynamics and may delay the emergen

171 ho initiated ART during acute HIV infection (AHI).

172 uman immunodeficiency virus (HIV) infection (AHI) can be defined as the time from HIV acquisition unt

173 uman immunodeficiency virus (HIV) infection (AHI) is limited by cost and decision algorithms to bette

174 uman immunodeficiency virus (HIV) infection (AHI) may account for a significant proportion of HIV-1 t

175 cute human immunodeficiency virus infection (AHI); however, the cost of nucleic acid amplification te

176 n immunodeficiency virus (HIV)-1 infections (AHI) may lead to prevention opportunities to mitigate hi

177 ed acute hepatitis C virus (HCV) infections (AHIs) have been mainly described in human immunodeficien

178 African ancestry was associated with a lower AHI, higher SaO2 and shorter event duration.

179 ificantly more impaired than all three lower AHI groups, indicating a dose-response impact of SDB.

180 ato-oxy lowered AHI by 63% (34-86%), from 28.5 (10.9-51.6) events/h to 7

181 n reducing AHI (CPAP AHI, 4.5 +/- 6.6/h; MAD AHI, 11.1 +/- 12.1/h; P < 0.01) but reported compliance

182 e adaptive servo-ventilation group, the mean AHI at 12 months was 6.6 events per hour.

183 In the randomized phase, the mean AHI score did not differ significantly from the 12-month

184 The mean AHI was 40.4 (SD, 18.9) and an average of 3.8 antihypert

185 The mean AHI was 47.9 at baseline and 20.8 at 6 months for the su

186 D], 46 +/- 9 years; Epworth 14 +/- 4; median AHI, 22/hour; interquartile ratio [IQR], 11-43/hour).

187 The median AHI result across the study cohort was 2.2 events per ho

188 The median AHI score at 12 months decreased 68%, from 29.3 events p

189 OSA was defined as mild to moderate (AHI, 15-29) or severe (AHI, >/=30).

190 0 or higher (classified as mild to moderate [AHI of 10 to 29] or severe [AHI >/=30]).

191 associated with increased cardiac mortality (AHI of </>/=15 events/h; log-rank: 6.6, 8.7, and 5.3, re

192 5.4] versus 2.0 [1.4-3.5]; P <0.05) and NREM AHI (50 [36-57] versus 24 [13-42] events h-1; P <0.05),

193 s breathing, but not an elevated obstructive AHI, is significantly associated with increased risk of

194 Cheyne-Stokes breathing but not obstructive AHI were significant predictors of incident heart failur

195 lexes (ICs), present in approximately 90% of AHI subjects, and compared the levels and antibody speci

196 All cases of AHI diagnosed in MSM in Lyon University Hospital from 20

197 of a pooling algorithm for the detection of AHI cases in a wide variety of settings.

198 ffectiveness ratios (ICERs) per diagnosis of AHI were calculated for programs with HIV prevalence rat

199 d AHI and WP-derived AHI (mean difference of AHI: -0.02+/-13.2).

200 We describe the epidemic of AHI in HIV-infected and HIV-negative MSM in Lyon, France

201 Identification of AHI by the dual EarlyTest screening algorithm is likely

202 pooling with NAAT for the identification of AHI cases; these models incorporate group testing theory

203 97, and 1.66 mg/L for SDB severity levels of AHI <1, 1 to 4.9, 5 to 14.9, and > or =15, respectively

204 s significantly associated with reduction of AHI (weighted mean difference [WMD], -33.8 [95% CI, -42.

205 (LR, 0.07; 95% CI, 0.03-0.19 at threshold of AHI >/=15/h).

206 Using a threshold of AHI >=15 per hour of sleep, the sensitivity and specific

207 otal of 67 individuals with obesity and OSA (AHI >= 10 events/h) underwent a sleep study and upper ai

208 f asthma with 4-year incidences of both OSA (AHI of >/=5 or positive airway pressure treatment) and O

209 into no OSA (AHI < 5 events/hour), mild OSA (AHI >= 5 and <15 events/hour), moderate OSA (AHI >= 15 a

210 AHI >= 5 and <15 events/hour), moderate OSA (AHI >= 15 and <30 events/hour), or severe OSA (AHI >= 30

211 ults, participants were grouped into no OSA (AHI < 5 events/hour), mild OSA (AHI >= 5 and <15 events/

212 I >= 15 and <30 events/hour), or severe OSA (AHI >= 30 events/hour).

213 o, EarlyTest was cost-savings (ie, ICERs per AHI diagnosis less than $13.000) when compared with the

214 Of the 15/20 patients with OSA on placebo (AHI > 10 events/hr), AHI was lowered by 74% (62-88%) (P

215 Multiple treatments for OSA reduce AHI, ESS scores, and blood pressure.

216 abbits restored KLF2 expression, and reduced AHI (7 +/- 2/h), RSNA (18 +/- 2% max) and arrhythmia inc

217 s programs were also associated with reduced AHI and excessive sleepiness.

218 al lesion (~65%) of RVLM-C1 neurones reduces AHI, respiratory variability, and respiratory-cardiovasc

219 AP was more efficacious than MAD in reducing AHI (CPAP AHI, 4.5 +/- 6.6/h; MAD AHI, 11.1 +/- 12.1/h;

220 vealed a significant association between REM AHI categories and the development of hypertension (P tr

221 han or equal to 5, a twofold increase in REM AHI was associated with 24% higher odds of hypertension

222 In individuals with non-REM AHI less than or equal to 5, a twofold increase in REM A

223 Non-REM AHI was not a significant predictor of hypertension in a

224 lent hypertension were most evident with REM AHI greater than or equal to 15.

225 leep apnea tests (HSAT) with the auto-scored AHI and ODI based on recording time.

226 t were overweight or obese, and 12% had SDB (AHI > or =5).

227 idence interval [CI], 0.5-2.7) for mild SDB (AHI, 5-14.9), 2.0 (95% CI, 0.7-5.5) for moderate SDB (AH

228 d an age-adjusted prevalence of minimal SDB (AHI >/= 5), moderate SDB (AHI >/= 15), and severe SDB (A

229 ce of minimal SDB (AHI >/= 5), moderate SDB (AHI >/= 15), and severe SDB (AHI >/= 30) of 25.8, 9.8, a

230 .9), 2.0 (95% CI, 0.7-5.5) for moderate SDB (AHI, 15-29.9), and 4.8 (95% CI, 1.7-13.2) for severe SDB

231 , and 4.8 (95% CI, 1.7-13.2) for severe SDB (AHI >/= 30) (P-trend = 0.0052).

232 , moderate SDB (AHI >/= 15), and severe SDB (AHI >/= 30) of 25.8, 9.8, and 3.9%, respectively.

233 .9 per 1,000 person-years in those with SDB (AHI >/=5 events/h) and 18.2 per 1,000 person-years in th

234 age +/- SD: 62.3 +/- 1.3 years) without SDB (AHI < 5).

235 as mild to moderate (AHI, 15-29) or severe (AHI, >/=30).

236 ild to moderate [AHI of 10 to 29] or severe [AHI >/=30]).

237 +/- 1.7 events/h), and 55 control siblings (AHI: 4.2 +/- 4.0 events/h).

238 3.2 +/- 26.3 events/h), 55 proband siblings (AHI: 11.8 +/- 16.6 events/h), 55 control subjects (AHI:

239 re in situ-quality NDVI temporal signatures, AHI "hypertemporal" data have the potential to improve s

240 Sixteen AHIs were identified from 28 655 persons screened.

241 apnea and hypopnea events per hour of sleep (AHI), but were associated with decreased mean lowest oxy

242 e interval [CI], 13%-21%) had a second-study AHI of at least 10 and 29 (10%) participants (95% CI, 7%

243 icipants (95% CI, 7%-14%) had a second-study AHI result of at least 15.

244 1.8 +/- 16.6 events/h), 55 control subjects (AHI: 2.1 +/- 1.7 events/h), and 55 control siblings (AHI

245 r testing for detecting severe OSA syndrome (AHI >/=30 and ESS score >10) was AUC 0.80 (95% CI, 0.78

246 ts experiencing a mild form of the syndrome (AHI < 15, n = 18), symptoms, treatment efficacy and sati

247 epwise multiple regression model showed that AHI was independently associated with FOXP3 DNA methylat

248 The AHI and genioglossus muscle responsiveness to negative e

249 The AHI decreased by 14.0 events/hour (95% CI, 3.3 to 24.6 e

250 The AHI index was female in 7/13 (54%) dyads.

251 Correlation between the AHI and ODI was 0.97 overall, 0.94 for supine, and 0.96

252 For most records, differences between the AHI and ODI were small, with only 14% of the records hav

253 an individual are not well described by the AHI.

254 POSA was defined independently for the AHI and ODI based on ratios of overall/non-supine event/

255 For the AHI results of at least 15, we estimate that about 2.5%

256 H(2) O) exhibited a greater reduction in the AHI (83 +/- 9 vs. 48 +/- 8% baseline, P < 0.001) and a l

257 eral plasma markers remained elevated in the AHI group (P < .001).

258 CCL2, and interleukin 6 (IL-6) levels in the AHI group to those in 18 healthy, uninfected controls.

259 tions across varying clinical cutoffs of the AHI.

260 Based on the AHI results, 178 participants (21.0%) demonstrated OSA:

261 Based on the AHI results, participants were grouped into no OSA (AHI

262 In a subgroup of nine patients, the AHI was also measured when the drugs were administered s

263 OA therapy reduced the AHI (30 +/- 5 vs. 11 +/- 2 events/h; P < 0.05), which wa

264 ither atomoxetine nor oxybutynin reduced the AHI when administered separately.

265 w adherence, because it reliably reduces the AHI when used, and the response to other therapies is va

266 and 7.2 events per hour, respectively); the AHI score was significantly higher (indicating more seve

267 lowing removal of 2.17 +/- 0.45 L by UF, the AHI decreased by 36% (43.8 +/- 20.3 to 28.0 +/- 17.7; P

268 structive sleep apnea was diagnosed when the AHI was 10 or higher (classified as mild to moderate [AH

269 d a dose response with SDB above a threshold AHI of 5.

270 1.40) gave the most evidence for linkage to AHI.

271 es in these structures, and relationships to AHI changes, were examined.Measurements and Main Results

272 % baseline, P < 0.001) and a lower treatment AHI (9 +/- 6 vs. 32 +/- 15 events h(-1) , P < 0.001) tha

273 Among other OSA-related variables, AHI in rapid eye movement sleep and time spent with oxyg

274 ercent agreements (positive, negative) were: AHI>=5=0.99, 0.78; AHI>=10=0.96, 0.89; and AHI>=15=0.96,

275 as genome-wide significantly associated with AHI (P < 5.7 x 10-5), and European and Amerindian ancest

276 latase (FECH), significantly associated with AHI and percentage time SaO2 < 90% after adjusting for m

277 large number of observations available with AHI resulted in improved NDVI temporal signatures that w

278 SS group, and beta power was correlated with AHI.

279 oved very difficult to find individuals with AHI either in longitudinal cohorts of subjects at high r

280 Men with AHI > or =30 were 58% more likely to develop heart failu

281 nd characterized individuals in Nigeria with AHI.

282 ciated with the hypoxemia index but not with AHI.

283 44.1 (SD 9.90) g/m(2.7) in participants with AHI > or = 30 (n=84) events per hour.

284 41.3 (SD 9.90) g/m(2.7) in participants with AHI < 5 (n=957) and 44.1 (SD 9.90) g/m(2.7) in participa

285 Compared with participants with AHI < 5, those with AHI > or = 30 had an adjusted odds r

286 RV254/SEARCH010 study participants with AHI underwent CSF (n = 89) and plasma (n = 146) sampling

287 w more widespread detection of patients with AHI and to affect HIV treatment outcomes and transmissio

288 redicting moderate/severe periodontitis with AHI score, age, and smoking status indicated a significa

289 ehavioral characteristics among persons with AHI and their referred partners.

290 Between 2012 and 2014, 46 persons with AHI in Malawi participated in a combined behavioral and

291 r = -0.51) emerged, but was not present with AHI.

292 The subjects with AHI >/= 20 were accepted as OSAS.

293 d with participants with AHI < 5, those with AHI > or = 30 had an adjusted odds ratio of 1.78 (95% co

294 Among men 40 to 70 years old, those with AHI > or =30 were 68% more likely to develop coronary he

295 ely to develop heart failure than those with AHI <5.

296 velop coronary heart disease than those with AHI <5.

297 azard of developing diabetes than those with AHI less than 5.

298 8.2 per 1,000 person-years in those without (AHI <5 events/h).

299 16 OSA children (8 male, 8.1 +/- 2.2 years, AHI:11.1 +/- 5.9 events/hr), and 200 control subjects (8

300 In those aged<60 years, AHI was significantly associated with higher odds of sys